Use of kidneys from anti-HCV positive donors
J.M. Morales(Research Institute Hospital 12 de Octubre), José L. Rodicio(Universidad Complutense de Madrid), F. Oppenheimer, Josep M. Campistol(Universitat de Barcelona), Amado Andrés(Hospital Universitario 12 De Octubre), Núria Esforzado(Hospital Clínic de Barcelona), Beatriz Domínguez‐Gil(Universidad de Zaragoza)
Cited by 7
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
|Journal of Hypertension|2009|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
|Blood Pressure|2009|899
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566